Evena updates wearable-connected ultrasound system


Evena Medical has introduced a new version of its DeepVu Ultrasound system. The update sees Evena simplify the operation and connectivity of DeepVu to step up its attempts to position the system as a convenient, easy-to-use alternative to traditional ultrasound technologies.

Version 4.0 of the system retains the core characteristics of earlier iterations of the product. Evena is still pitching DeepVu as a way for new users of ultrasound systems to capture images from up to 100 mm below the surface of the skin. The system connects to a clamp-attached screen, a Google Glass-style wearable and other devices to display ultrasound images. And it features an auto-scan mode and built-in measurement, calculation and reporting tools.

Evena is seeking to build on the flexibility and convenience of the system with version 4.0.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

Wireless connectivity is a big part of its pitch. This allows users to relay images captured by DeepVu to doctors in other parts of their medical facility and beyond. Doctors can view the images on devices including iPads and Evena’s aforementioned Eyes-On Clinical Glasses. The glasses are designed to enable users to view a patient’s vascular system at the bedside to make it easier to access veins.

“The DeepVu Ultrasound 4.0 system offers medical professionals an advanced mobile and wearable ultrasound option for adult primary care, pediatrics, emergency medical care and other medical specialties,” Evena CEO Frank Ball said in a statement. “With Evena’s Eyes-On Glasses, clinicians can visualize veins, organs and other tissue deep beneath the skin with superior, real-time imaging in front of their eyes with simple, hands-free operation.”

Other changes to DeepVu 4.0 include a slimmed-down pocket-sized transducer to convert ultrasound waves to electrical signals and the switch to one-button operation to make life easier for users.

Evena, formally known as VuStik, pulled in the first $5 million of a planned $15 million Series B in 2014 to fund the rollout of its technologies. The first tranche of the Series B formed part of a deal that gave Evena a route into markets in the Middle East and North Africa.


Suggested Articles

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.

Since launching Grail into the world in 2016, Illumina has watched the cancer blood test developer grow into a multibillion-dollar startup enterprise.